

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

survminer

RRID:SCR_021094

Type: Tool

Proper Citation

survminer (RRID:SCR_021094)

Resource Information

URL: <https://rdocumentation.org/packages/survminer/versions/0.4.9>

Proper Citation: survminer (RRID:SCR_021094)

Description: Software R package provides functions for facilitating survival analysis and visualization.

Resource Type: data analysis software, data processing software, data visualization software, software application, software resource

Keywords: survival analysis, survival visualization, R

Availability: Free, Available for download, Freely available

Resource Name: survminer

Resource ID: SCR_021094

License: GPL-2

Record Creation Time: 20220129T080353+0000

Record Last Update: 20260905T132934+0000

Ratings and Alerts

No rating or validation information has been found for survminer.

No alerts have been found for survminer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 133 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Fields BC, et al. (2026) High dietary fiber is associated with improved outcomes in patients with melanoma and sarcoma treated with immunotherapy regardless of gut microbiome dysbiosis and social vulnerability. *Cancer*, 132(6), e70335.

Köcher S, et al. (2026) Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. *The Journal of clinical investigation*, 136(6).

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. *PLoS biology*, 24(1), e3003603.

Hofvander J, et al. (2026) Transcriptomic Subgroups in Soft Tissue Tumors Correlate with Morphologic Subtype, Genomic Features, and Outcome. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1825.

Yoshimoto D, et al. (2026) Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer. *Cancer immunology research*, 14(1), 77.

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. *JGH open : an open access journal of gastroenterology and hepatology*, 10(1), e70331.

Testa S, et al. (2026) A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma. *Cancer research communications*, 6(6), 1295.

Eriksson J, et al. (2026) Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. *Cancer research*, 86(7), 1724.

Xia Z, et al. (2026) PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer. *Cancer research*, 86(12), 3040.

Dermawan JK, et al. (2026) Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma. *Science advances*, 12(9), eaea6453.

Stoiber S, et al. (2026) [18F]FDG PET/CT multiomics identifies Hedgehog-driven HPV-negative head and neck squamous cell carcinoma. *Molecular cancer*, 25(1).

Wong JP, et al. (2026) NF- κ B and STAT3 signaling uniquely stratify survival in female glioblastoma patients. *iScience*, 29(2), 114761.

Sherif S, et al. (2026) A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. *Cancers*, 18(9).

Fresques T, et al. (2026) YAP1 Dysfunction Promotes Molecular Properties Linked to Breast Cancer Susceptibility. *Cancer prevention research (Philadelphia, Pa.)*, 19(4), 203.

Bharadwaj S, et al. (2026) Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2508.

Lee JK, et al. (2026) The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2653.

Sato K, et al. (2026) Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma. *Cancer research communications*, 6(2), 260.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Tirtei E, et al. (2026) Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials. *Cancer research communications*, 6(4), 857.

Andersen L, et al. (2026) Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes. *Cancer research communications*, 6(4), 811.